-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to incomplete statistics, since 2022, at least 9 pharmaceutical and biological companies, including CanSino, Mindray Medical, Aide Bio, Tigermed, and Haier Bio, have issued repurchase plans, and most of the companies have repurchased more than 1 billion
.
Among them, Mindray Medical has attracted the attention of the industry with a repurchase fund of 1 billion yuan
.
On February 10, the domestic medical device giant Mindray Medical announced that Mindray Medical will carry out its second major repurchase within half a year.
1 billion yuan will be repurchased within 12 months, and the repurchase price will not exceed 400 yuan per share
.
According to the "Administrative Measures for Employee Stock Ownership Plans in 2022", Mindray Medical will increase its net profit by 20% each year in the next three years as the attribution condition for employee stock ownership
.
This assessment objective fully demonstrates the company's confidence in its future performance
.
Tigermed announced on the evening of February 14 that the company plans to use its own funds or self-raised funds to repurchase some of the company's A shares through centralized bidding transactions, with a repurchase amount of not less than 250 million yuan and not more than 50 million yuan.
100 million yuan, and the repurchase price is not less than 120 yuan per share
.
Tigermed is a domestic comprehensive clinical contract research organization, mainly providing customers with comprehensive clinical research solutions such as design, implementation and management services
.
Also on February 14, Aide Bio also announced that it plans to repurchase shares for 100 million to 200 million yuan, the repurchase price does not exceed 95 yuan per share, and the repurchase period does not exceed 12 months
.
The company is mainly committed to the development and production of molecular diagnostic overall solutions/series products that comply with national laws and industry norms and serve precision tumor medicine to meet the clinical testing needs of tumor patients
.
CanSino announced at the end of January that the company will repurchase the company's shares in a centralized bidding transaction.
The repurchase amount is capped at 300 million yuan and the repurchase price is capped at 446.
78 yuan per share.
The repurchase period does not exceed 12 months
.
The company is an innovative vaccine company, mainly engaged in the research and development and production of high-quality human vaccines
.
Judging from the reasons why the above-mentioned pharmaceutical companies have thrown out share repurchase plans, some companies are based on having great confidence in the company's stock price. .
For example, Mindray Medical, its medical device industry is in a stage of rapid development, and the pace of domestic substitution of imports is accelerating
.
It is generally believed in the industry that the Chinese medical device giants are expected to undertake new opportunities in the market
.
Mindray Medical also said in the survey that no matter from the company's brand influence, control of core technologies, product market performance, overall solutions across production lines, or from the stable growth of company profits and cash flow, all make The company is full of confidence in the future development prospects and performance growth
.
The third quarterly report for 2021 shows that the company achieved a main income of 19.
392 billion yuan, a year-on-year increase of 20.
72%; the net profit attributable to the parent was 6.
663 billion yuan, a year-on-year increase of 24.
23%.
In addition, there are many companies to motivate employees and enhance investors' confidence in the company.
.
For example, Tigermed stated that the repurchase plan is to promote the healthy, stable and long-term development of the company, enhance investors' confidence in the company, safeguard the interests of the majority of investors, and at the same time, further establish and improve the company's long-term incentive mechanism
.
CanSino also stated in the announcement that the repurchased shares will be used for employee stock ownership plans or equity incentives
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among them, Mindray Medical has attracted the attention of the industry with a repurchase fund of 1 billion yuan
.
On February 10, the domestic medical device giant Mindray Medical announced that Mindray Medical will carry out its second major repurchase within half a year.
1 billion yuan will be repurchased within 12 months, and the repurchase price will not exceed 400 yuan per share
.
According to the "Administrative Measures for Employee Stock Ownership Plans in 2022", Mindray Medical will increase its net profit by 20% each year in the next three years as the attribution condition for employee stock ownership
.
This assessment objective fully demonstrates the company's confidence in its future performance
.
Tigermed announced on the evening of February 14 that the company plans to use its own funds or self-raised funds to repurchase some of the company's A shares through centralized bidding transactions, with a repurchase amount of not less than 250 million yuan and not more than 50 million yuan.
100 million yuan, and the repurchase price is not less than 120 yuan per share
.
Tigermed is a domestic comprehensive clinical contract research organization, mainly providing customers with comprehensive clinical research solutions such as design, implementation and management services
.
Also on February 14, Aide Bio also announced that it plans to repurchase shares for 100 million to 200 million yuan, the repurchase price does not exceed 95 yuan per share, and the repurchase period does not exceed 12 months
.
The company is mainly committed to the development and production of molecular diagnostic overall solutions/series products that comply with national laws and industry norms and serve precision tumor medicine to meet the clinical testing needs of tumor patients
.
CanSino announced at the end of January that the company will repurchase the company's shares in a centralized bidding transaction.
The repurchase amount is capped at 300 million yuan and the repurchase price is capped at 446.
78 yuan per share.
The repurchase period does not exceed 12 months
.
The company is an innovative vaccine company, mainly engaged in the research and development and production of high-quality human vaccines
.
Judging from the reasons why the above-mentioned pharmaceutical companies have thrown out share repurchase plans, some companies are based on having great confidence in the company's stock price. .
For example, Mindray Medical, its medical device industry is in a stage of rapid development, and the pace of domestic substitution of imports is accelerating
.
It is generally believed in the industry that the Chinese medical device giants are expected to undertake new opportunities in the market
.
Mindray Medical also said in the survey that no matter from the company's brand influence, control of core technologies, product market performance, overall solutions across production lines, or from the stable growth of company profits and cash flow, all make The company is full of confidence in the future development prospects and performance growth
.
The third quarterly report for 2021 shows that the company achieved a main income of 19.
392 billion yuan, a year-on-year increase of 20.
72%; the net profit attributable to the parent was 6.
663 billion yuan, a year-on-year increase of 24.
23%.
In addition, there are many companies to motivate employees and enhance investors' confidence in the company.
.
For example, Tigermed stated that the repurchase plan is to promote the healthy, stable and long-term development of the company, enhance investors' confidence in the company, safeguard the interests of the majority of investors, and at the same time, further establish and improve the company's long-term incentive mechanism
.
CanSino also stated in the announcement that the repurchased shares will be used for employee stock ownership plans or equity incentives
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
